Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Resource

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    544 result(s) found for: Resource. Displaying page 1 of 28.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-001061-42 Sponsor Protocol Number: 0881A3-405 Start Date*: 2006-07-31
    Sponsor Name:Wyeth Pharmaceuticals France, Wyeth Research Division
    Full Title: An open-label, multicentre, supplementary and extension study of Etanercept in subjects with Ankylosing Spondylitis (AS)
    Medical condition: Ankylosing spondylitis (AS).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-005262-35 Sponsor Protocol Number: 16401 Start Date*: 2013-07-08
    Sponsor Name:Bayer HealthCare AG
    Full Title: BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi...
    Medical condition: Clinically isolated syndrome (CIS) and multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    14.1 10029205 - Nervous system disorders 10071068 Clinically isolated syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) PT (Completed) HU (Completed) CZ (Completed) NO (Completed) AT (Completed) FI (Completed) DK (Completed) GB (Completed) ES (Completed) IT (Completed) SI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000636-15 Sponsor Protocol Number: 12/201/02 Start Date*: 2015-05-27
    Sponsor Name:Bangor University
    Full Title: A randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica.
    Medical condition: Sciatica is a symptom defined as unilateral, well-localised leg pain, with a sharp, shooting or burning quality, that approximates to the dermatomal distribution of the sciatic nerve down the poste...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003622-45 Sponsor Protocol Number: TAK-771-3004 Start Date*: 2022-12-06
    Sponsor Name:Takeda
    Full Title: A Phase 3, Open-label, Non-controlled Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Efficacy of TAK-771 in Japanese Subjects with Primary Immunodeficiency Diseases (PID)
    Medical condition: Primary Immunodeficiency Diseases (PID)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10064859 Primary immunodeficiency syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-001365-32 Sponsor Protocol Number: 19CX5006 Start Date*: 2019-07-25
    Sponsor Name:Imperial Joint Research Compliance Office
    Full Title: IP4- CHRONOS: Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001186 Adenocarcinoma of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-003703-19 Sponsor Protocol Number: 18-002 Start Date*: 2020-04-20
    Sponsor Name:RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty
    Full Title: The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Randomized Trial
    Medical condition: Nutritionally high-risk critically ill mechanically ventilated patients. In this sub-study, eligible and enrolled patients randomized to the high protein dose group will achieve its protein goals b...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001176-31 Sponsor Protocol Number: 19215 Start Date*: 2017-09-22
    Sponsor Name:Bayer AG,
    Full Title: BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies
    Medical condition: Clinically-isolated syndrome (CIS) and multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10071068 Clinically isolated syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) SE (Completed) GB (Completed) AT (Completed) CZ (Completed) FI (Completed) DK (Completed) BE (Completed) FR (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022726-33 Sponsor Protocol Number: 251001 Start Date*: 2011-03-24
    Sponsor Name:Baxter Innovations GmbH
    Full Title: BAX326 (recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients with Severe (FIX level < 1%) or Moderately Severe (FIX level 1- 2%) Hemo...
    Medical condition: Previously treated patients (PTPs) with severe (FIX level < 1%) or moderately severe (FIX level 1- 2%) hemophilia B.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BG (Completed) CZ (Completed) GB (Completed) DE (Prematurely Ended) SE (Completed) PL (Completed) ES (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005066-38 Sponsor Protocol Number: CINC424AGB02 Start Date*: 2012-03-09
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: A UK open-label, multicentre, exploratory Phase II study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelof...
    Medical condition: primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV MF) or Post essential thrombocythemia myelofibrosis (PET-MF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013817-93 Sponsor Protocol Number: 2190 Start Date*: 2009-08-27
    Sponsor Name:North Bristol NHS Trust, Research and Development
    Full Title: Arthroplasty Pain Experience Study (APEX): A randomised controlled trial to determine if local wound infiltration reduces chronic pain after lower limb arthroplasty.
    Medical condition: hip and knee osteoarthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000583-16 Sponsor Protocol Number: 312041 Start Date*: 2009-03-13
    Sponsor Name:Bayer Schering Pharma AG (BSP)
    Full Title: Multi-center, randomized comparison study to eVALUatE outcomes and resource needs of imaging and treatment following Primovist-enhanced MRI of the liver in comparison to extracellular contrast medi...
    Medical condition: Patients with history of colorectal cancer and known or suspected metachronous liver metastasis(es) scheduled to undergo contrast-enhanced tomographic imaging (i.e. CE-MRI or CE-CT) of the liver
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) NL (Completed) ES (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002654-21 Sponsor Protocol Number: S187.4.001 Start Date*: 2005-08-08
    Sponsor Name:Solvay Pharmaceuticals GmbH
    Full Title: A long-term health economics study of intraduodenal levodopa (Duodopa®) in routine care for patients with advanced idiopathic Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia.
    Medical condition: Treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfa...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2016-002259-11 Sponsor Protocol Number: GRT-ZVO-2016-01 Start Date*: 2016-10-10
    Sponsor Name:GRUNENTHAL PHARMA S.A.
    Full Title: A multicenter, open-label, single-arm, Phase IIIb trial to evaluate the effectiveness, safety, tolerability, usability and health economics resource utilization of Zalviso® for management of acute ...
    Medical condition: Acute moderate to severe postoperative pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-003351-11 Sponsor Protocol Number: GPRI-19102-TRA Start Date*: 2019-12-19
    Sponsor Name:GPRI
    Full Title: Triple therapy effectiveness in COPD patients with characteristics of asthma: A pragmatic Primary Care trial - The TRACkER trial
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD) patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003686-17 Sponsor Protocol Number: I4V-MC-JADY Start Date*: 2013-05-29
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SK (Completed) CZ (Prematurely Ended) BE (Completed) PL (Completed) SE (Completed) GB (Completed) HU (Completed) AT (Completed) DK (Completed) DE (Completed) PT (Completed) NL (Completed) ES (Completed) LV (Completed) LT (Completed) GR (Completed) SI (Completed) HR (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005601-46 Sponsor Protocol Number: 000081 Start Date*: 2013-05-15
    Sponsor Name:Ferring International Pharmascience Center US, Inc.
    Full Title: A Multicenter, Open-label, Safety and Tolerability Extension Trial of 5 mg and 10 mg Elobixibat Daily in the Treatment of Chronic Idiopathic Constipation
    Medical condition: Chronic idiopathic constipation
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004856 10072118 Chronic idiopathic constipation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) SK (Completed) HU (Completed) CZ (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-001498-63 Sponsor Protocol Number: BIO101-CL05 Start Date*: 2020-07-22
    Sponsor Name:Biophytis S.A.
    Full Title: Adaptive design phase 2 to 3, randomized, double- blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterior...
    Medical condition: Confirmed infection with SARS-CoV-2 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047465 Viral infections NEC HLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-004748-37 Sponsor Protocol Number: MK-0476-367 Start Date*: 2015-04-03
    Sponsor Name:MSD Korea LTD.
    Full Title: Korean Study of “Real-world” Montelukast Use in Mild Asthmatic Children with Concomitant Allergic Rhinitis
    Medical condition: mild asthma and allergic rhinitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-005965-20 Sponsor Protocol Number: ML20938 Start Date*: 2007-03-07
    Sponsor Name:Roche AB
    Full Title: EFFECTS OF THREE TREATMENT STRATEGIES ON ANEMIA AND QUALITY OF LIFE IN PATIENTS WITH SOLID TUMORS OR LYMPHOPROLIFERATIVE MALIGNANCIES: A RANDOMIZED 3-ARM STUDY ON ACTIVE (A) OR CONVENTIONAL (C) TRA...
    Medical condition: Anemia in patients with cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004611-50 Sponsor Protocol Number: CCTU0228 Start Date*: 2019-06-14
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of rituximab in treating de novo or relapsing NS in p...
    Medical condition: Minimal Change Disease (MCD) and Focal segmental glomerulosclerosis (FSGS)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 10:40:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA